CARGO Therapeutics to Participate in Upcoming Investor Conferences
28 mai 2024 08h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27 mai 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
17 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Monthly information on share capital and company voting rights
16 mai 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
14 mai 2024 10h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 mai 2024 16h47 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
13 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
06 mai 2024 02h00 HE
|
Cellectis Inc.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02 mai 2024 16h30 HE
|
Cellectis Inc.
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer